Figure 3.

Changes in VSMCs phenotype following silencing and overexpression of SNHG1. (A) α-SMA, (B) SM22a and (C) OPN mRNA expression following overexpressing or silencing of SNHG1 combining rapamycin treatment in VSMCs; (D-G) SM22a, α-SMA and OPN protein levels following silencing or overexpression of SNHG1 combing with rapamycin treatment. Data were shown as mean ± standard deviation of a representative experiment performed in three independent replicates. *P<0.05, **P<0.01, ***P<0.001. VSMCs, vascular smooth muscle cells; SNHG1, small ribosome housekeeping gene RNA1; α-SMA, α-smooth muscle actin; SM22a, smooth muscle protein 22a; OPN, osteopontin; sh, short hairpin; NC, negative control; OE, overexpression; Rapa, rapamycin.